Asunaprevir | BMS-650032 | CAS#630420-16-5 | NS3 inhibitor

MedKoo Cat#: 326709 | Name: Asunaprevir

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Asunaprevir, also known as BMS-650032, is an inhibitor of the hepatitis C virus enzyme serine protease NS3. Asunaprevir is being tested in combination with pegylated interferon and ribavirin, as well as in interferon-free regimens with other direct-acting antiviral agents including daclatasvir.

Chemical Structure

Asunaprevir

CAS#630420-16-5

Theoretical Analysis

MedKoo Cat#: 326709

Name: Asunaprevir

CAS#: 630420-16-5

Chemical Formula: C35H46ClN5O9S

Exact Mass: 747.2705

Molecular Weight: 748.29

Elemental Analysis: C, 56.18; H, 6.20; Cl, 4.74; N, 9.36; O, 19.24; S, 4.28

Price and Availability

Size	Price	Availability
25mg	USD 350.00	2 Weeks
50mg	USD 600.00	2 Weeks
100mg	USD 950.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

BMS-650032; BMS 650032; BMS650032; Asunaprevir. brand name: Sunvepra

IUPAC/Chemical Name

1,1-dimethylethyl ((1S)-1-{((2S,4R)-4-(7-chloro-4-methoxyisoquinolin-1-yloxy)-2-({(1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-ethenylcyclopropyl}carbamoyl) pyrrolidin-1-yl)carbonyl}-2,2-dimethylpropyl)carbamate

InChi Key

XRWSZZJLZRKHHD-WVWIJVSJSA-N

InChi Code

InChI=1S/C35H46ClN5O9S/c1-9-19-16-35(19,31(44)40-51(46,47)22-11-12-22)39-28(42)25-15-21(49-29-24-14-20(36)10-13-23(24)26(48-8)17-37-29)18-41(25)30(43)27(33(2,3)4)38-32(45)50-34(5,6)7/h9-10,13-14,17,19,21-22,25,27H,1,11-12,15-16,18H2,2-8H3,(H,38,45)(H,39,42)(H,40,44)/t19-,21-,25+,27-,35-/m1/s1

SMILES Code

O=C(OC(C)(C)C)N[C@H](C(N1[C@H](C(N[C@@]2(C(NS(=O)(C3CC3)=O)=O)[C@H](C=C)C2)=O)C[C@@H](OC4=NC=C(OC)C5=C4C=C(Cl)C=C5)C1)=O)C(C)(C)C

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 748.29 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Hernandez D, Yu F, Huang X, Kirov S, Pant S, McPhee F. Impact of Pre-existing NS5A-L31 or -Y93H Minor Variants on Response Rates in Patients Infected with HCV Genotype-1b Treated with Daclatasvir/Asunaprevir. Adv Ther. 2016 Jun 10. [Epub ahead of print] PubMed PMID: 27287851. 2: Kanda T, Yasui S, Nakamura M, Suzuki E, Arai M, Haga Y, Sasaki R, Wu S, Nakamoto S, Imazeki F, Yokosuka O. Daclatasvir plus Asunaprevir Treatment for Real-World HCV Genotype 1-Infected Patients in Japan. Int J Med Sci. 2016 May 12;13(6):418-23. doi: 10.7150/ijms.15519. eCollection 2016. PubMed PMID: 27279790; PubMed Central PMCID: PMC4893555. 3: Sohda T, Yamauchi E, Anan A, Yokoyama K, Fukunaga A, Yamauchi R, Fukuda S, Takata K, Tanaka T, Hanano T, Kitamura Y, Morihara D, Takeyama Y, Irie M, Shakado S, Sakisaka S. Non-response to daclatasvir and asunaprevir therapy in patients co-infected with hepatitis C virus genotypes 1 and 2. Hepatol Res. 2016 Jun 4. doi: 10.1111/hepr.12758. [Epub ahead of print] PubMed PMID: 27260815. 4: Akuta N, Sezaki H, Suzuki F, Kawamura Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki Y, Arase Y, Ikeda K, Kumada H. Favorable efficacy of daclatasvir plus asunaprevir in treatment of elderly Japanese patients infected with HCV genotype 1b aged 70 and older. J Med Virol. 2016 Jun 3. doi: 10.1002/jmv.24592. [Epub ahead of print] PubMed PMID: 27256744. 5: Iio E, Shimada N, Abe H, Atsukawa M, Yoshizawa K, Takaguchi K, Eguchi Y, Nomura H, Kuramitsu T, Kang JH, Matsui T, Hirashima N, Tsubota A, Kusakabe A, Hasegawa I, Miyaki T, Shinkai N, Fujiwara K, Nojiri S, Tanaka Y. Efficacy of daclatasvir/asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1. J Gastroenterol. 2016 May 28. [Epub ahead of print] PubMed PMID: 27236547. 6: Ogawa E, Furusyo N, Yamashita N, Kawano A, Takahashi K, Dohmen K, Nakamuta M, Satoh T, Nomura H, Azuma K, Koyanagi T, Kotoh K, Shimoda S, Kajiwara E, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group. Effectiveness and safety of daclatasvir plus asunaprevir for HCV genotype 1b patients aged 75 and over with or without cirrhosis. Hepatol Res. 2016 May 3. doi: 10.1111/hepr.12738. [Epub ahead of print] PubMed PMID: 27142311. 7: Kamada T, Furuta K, Tomioka H. Drug-induced lung injury associated with combination therapy of daclatasvir and asunaprevir: The first case report. Respir Investig. 2016 May;54(3):207-10. doi: 10.1016/j.resinv.2015.12.003. Epub 2016 Jan 18. PubMed PMID: 27108017. 8: Miyazaki R, Miyagi K. Effect and Safety of Daclatasvir-Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b -Infected Patients on Hemodialysis. Ther Apher Dial. 2016 Apr 21. doi: 10.1111/1744-9987.12407. [Epub ahead of print] PubMed PMID: 27098678. 9: Kao JH, Lee YJ, Heo J, Ahn SH, Lim YS, Peng CY, Chang TT, Torbeyns A, Hughes E, Bhore R, Noviello S. All-oral daclatasvir plus asunaprevir for chronic HCV genotype 1b infection: a sub-analysis in Asian patients from the HALLMARK DUAL study. Liver Int. 2016 Mar 24. doi: 10.1111/liv.13128. [Epub ahead of print] PubMed PMID: 27009831. 10: Wei L, Zhang M, Xu M, Chuang WL, Lu W, Xie W, Jia Z, Gong G, Li Y, Bae SH, Yang YF, Xie Q, Lin S, Chen X, Niu J, Jia J, Garimella T, Torbeyns A, McPhee F, Treitel M, Yin PD, Mo L. A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin. J Gastroenterol Hepatol. 2016 Mar 22. doi: 10.1111/jgh.13379. [Epub ahead of print] PubMed PMID: 27003037. 11: Matsumoto N, Ikeda H, Shigefuku R, Hattori N, Watanabe T, Matsunaga K, Hiraishi T, Tamura T, Noguchi Y, Fukuda Y, Ishii T, Okuse C, Sato A, Suzuki M, Itoh F. Hemoglobin Decrease with Iron Deficiency Induced by Daclatasvir plus Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b. PLoS One. 2016 Mar 18;11(3):e0151238. doi: 10.1371/journal.pone.0151238. eCollection 2016. PubMed PMID: 26990758; PubMed Central PMCID: PMC4798293. 12: Sato K, Yamazaki Y, Ohyama T, Kobayashi T, Horiguchi N, Kakizaki S, Kusano M, Yamada M. Combination therapy with daclatasvir and asunaprevir for dialysis patients infected with hepatitis C virus. World J Clin Cases. 2016 Mar 16;4(3):88-93. doi: 10.12998/wjcc.v4.i3.88. PubMed PMID: 26989674; PubMed Central PMCID: PMC4792170. 13: Toyoda H, Kumada T, Tada T, Takaguchi K, Ishikawa T, Tsuji K, Zeniya M, Iio E, Tanaka Y. Erratum to: Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis. J Gastroenterol. 2016 Mar 7. [Epub ahead of print] PubMed PMID: 26948482. 14: Sato A, Ishii T, Adachi K, Kumon D, Tamura T, Noguchi Y, Matsumoto N, Okuse C. Sustained virological response after a 17-day treatment with daclatasvir plus asunaprevir in a cirrhotic patient with hepatitis C virus genotype 1b and null response for peginterferon ribavirin therapy. Clin J Gastroenterol. 2016 Apr;9(2):89-92. doi: 10.1007/s12328-016-0630-2. Epub 2016 Feb 20. PubMed PMID: 26896968. 15: Uchida Y, Kouyama JI, Naiki K, Sugawarav K, Inao M, Imai Y, Nakayama N, Mochida S. Development of rare RAVs that are extremely tolerant against NS5A inhibitors during daclatasvir/asunaprevir therapy Via a Two-Hit mechanism. Hepatol Res. 2016 Feb 15. doi: 10.1111/hepr.12673. [Epub ahead of print] PubMed PMID: 26878268. 16: Toyoda H, Kumada T, Tada T, Takaguchi K, Ishikawa T, Tsuji K, Zeniya M, Iio E, Tanaka Y. Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis. J Gastroenterol. 2016 Feb 12. [Epub ahead of print] PubMed PMID: 26872889. 17: Ozeki I, Nakajima T, Yamaguchi M, Kimura M, Arakawa T, Kuwata Y, Ohmura T, Sato T, Hige S, Karino Y, Toyota J. Successful achievement of sustained virological response to triple combination therapy containing simeprevir in two patients with chronic hepatitis C who had failed asunaprevir-daclatasvir combination therapy. Hepatol Res. 2016 Feb 9. doi: 10.1111/hepr.12667. [Epub ahead of print] PubMed PMID: 26857426. 18: Suzuki F. [Daclatasvir plus asunaprevir combination therapy for patients with chronic hepatitis C]. Nihon Rinsho. 2015 Dec;73 Suppl 9:257-61. Japanese. PubMed PMID: 26845941. 19: Swallow E, Kelley C, Signorovitch J, Wygant G, McPhee F. Daclatasvir + asunaprevir versus sofosbuvir/ledipasvir for hepatitis C genotype 1 in Japanese patients: an indirect comparison. J Comp Eff Res. 2016 May;5(3):273-9. doi: 10.2217/cer.15.69. Epub 2016 Jan 21. PubMed PMID: 26793987. 20: Suda G, Kudo M, Nagasaka A, Furuya K, Yamamoto Y, Kobayashi T, Shinada K, Tateyama M, Konno J, Tsukuda Y, Yamasaki K, Kimura M, Umemura M, Izumi T, Tsunematsu S, Sato F, Terashita K, Nakai M, Horimoto H, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N. Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C. J Gastroenterol. 2016 Jan 14. [Epub ahead of print] PubMed PMID: 26768604.